A simple competitive assay to determine peptide affinity for HLA class II molecules: A useful tool for epitope prediction

Journal of Immunological Methods

Volumn 371, Issue 1-2, 2011, Pages 97-105

  Bernardeau, K ^a   Kerzhero, J ^b   Fortun, A ^a   Moreau Aubry, A ^c   Favry, E ^b   Echasserieau, K ^a   Tartour, E ^d   Maillere B ^b   Lang, F ^a,c  

^a Team 12   (France)

^b SERVICE DE CHIMIE BIOORGANIQUE ET DE MARQUAGE   (France)

^c UNIVERSITÉ DE NANTES   (France)

^d PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

Author keywords

Class II HLA; Competition assay; Peptide affinity; T cell epitopes; Tumor antigens

Indexed keywords

EPITOPE; HLA ANTIGEN CLASS 2; HLA DP ANTIGEN; PEPTIDE; TELOMERASE REVERSE TRANSCRIPTASE;

ACCURACY; ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BINDING COMPETITION; CONTROLLED STUDY; CYTOMETRY; HLA SYSTEM; HUMAN; INSECT CELL; NONHUMAN; PREDICTION; PRIORITY JOURNAL; T LYMPHOCYTE;

AMINO ACID SEQUENCE; ANIMALS; BINDING, COMPETITIVE; BIOTINYLATION; CELL LINE; DROSOPHILA; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-DP ANTIGENS; HUMANS; IMMUNOASSAY; MOLECULAR SEQUENCE DATA; PEPTIDES; RECOMBINANT PROTEINS; T-LYMPHOCYTES; TELOMERASE;

HEXAPODA;

EID: 79960947720     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2011.06.018     Document Type: Article

References (24)

1. Ayyoub M., Dojcinovic D., Pignon P., Raimbaud I., Schmidt J., Luescher I., Valmori D. Monitoring of NY-ESO-1 specific CD4+ T cells using molecularly defined MHC class II/His-tag-peptide tetramers. Proc. Natl. Acad. Sci. USA 2010, 107:7437.
2. Bui H.H., Sidney J., Peters B., Sathiamurthy M., Sinichi A., Purton K.A., Mothe B.R., Chisari F.V., Watkins D.I., Sette A. Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications. Immunogenetics 2005, 57:304.
3. Busson M., Castelli F.A., Wang X.F., Cohen W.M., Charron D., Menez A., Maillere B. Prediction of CD4(+) T cell epitopes restricted to HLA-DP4 molecules. J. Immunol. Methods 2006, 317:144.
4. Call M.J., Xing X., Cuny G.D., Seth N.P., Altmann D.M., Fugger L., Krogsgaard M., Stein R.L., Wucherpfennig K.W. In vivo enhancement of peptide display by MHC class II molecules with small molecule catalysts of peptide exchange. J. Immunol. 2009, 182:6342.
5. Castelli F.A., Buhot C., Sanson A., Zarour H., Pouvelle-Moratille S., Nonn C., Gahery-Segard H., Guillet J.G., Menez A., Georges B., Maillere B. HLA-DP4, the most frequent HLA II molecule, defines a new supertype of peptide-binding specificity. J. Immunol. 2002, 169:6928-6934.
6. Castelli F.A., Leleu M., Pouvelle-Moratille S., Farci S., Zarour H.M., Andrieu M., Auriault C., Menez A., Georges B., Maillere B. Differential capacity of T cell priming in naive donors of promiscuous CD4+ T cell epitopes of HCV NS3 and Core proteins. Eur. J. Immunol. 2007, 37:1513.
7. Crawford F., Kozono H., White J., Marrack P., Kappler J. Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes. Immunity 1998, 8:675.
8. Justesen S., Harndahl M., Lamberth K., Nielsen L.L., Buus S. Functional recombinant MHC class II molecules and high-throughput peptide-binding assays. Immunome Res 2009, 5:2.
9. Kobayashi H., Celis E. Peptide epitope identification for tumor-reactive CD4 T cells. Curr. Opin. Immunol. 2008, 20:221.
10. Liu J.P., Chen W., Schwarer A.P., Li H. Telomerase in cancer immunotherapy. Biochim. Biophys. Acta 2010, 1805:35.
11. Marin-Esteban V., Falk K., Rotzschke O. "Chemical analogues" of HLA-DM can induce a peptide-receptive state in HLA-DR molecules. J. Biol. Chem. 2004, 279:50684.
12. Melief C.J., van der Burg S.H. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat. Rev. Cancer 2008, 8:351.
13. Natarajan S.K., Assadi M., Sadegh-Nasseri S. Stable peptide binding to MHC class II molecule is rapid and is determined by a receptive conformation shaped by prior association with low affinity peptides. J. Immunol. 1999, 162:4030.
14. Nielsen M., Lundegaard C., Lund O. Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method. BMC Bioinforma. 2007, 8:238.
15. Novak E.J., Liu A.W., Nepom G.T., Kwok W.W. MHC class II tetramers identify peptide-specific human CD4(+) T cells proliferating in response to influenza A antigen. J. Clin. Invest. 1999, 104:R63.
16. Pu Z., Lovitch S.B., Bikoff E.K., Unanue E.R. T cells distinguish MHC-peptide complexes formed in separate vesicles and edited by H2-DM. Immunity 2004, 20:467.
17. Rammensee H., Bachmann J., Emmerich N.P., Bachor O.A., Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999, 50:213.
18. Schultz E.S., Lethe B., Cambiaso C.L., Van Snick J., Chaux P., Corthals J., Heirman C., Thielemans K., Boon T., van der Bruggen P. A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes. Cancer Res. 2000, 60:6272.
19. Wang J.C., Livingstone A.M. Cutting edge: CD4+ T cell help can be essential for primary CD8+ T cell responses in vivo. J. Immunol. 2003, 171:6339.
20. Wang X.F., Cohen W.M., Castelli F.A., Almunia C., Lethe B., Pouvelle-Moratille S., Munier G., Charron D., Menez A., Zarour H.M., van der Bruggen P., Busson M., Maillere B. Selective identification of HLA-DP4 binding T cell epitopes encoded by the MAGE-A gene family. Cancer Immunol. Immunother. 2007, 56:807.
21. Wang X.F., Kerzerho J., Adotevi O., Nuyttens H., Badoual C., Munier G., Oudard S., Tu S., Tartour E., Maillere B. Comprehensive analysis of HLA-DR- and HLA-DP4-restricted CD4+ T cell response specific for the tumor-shared antigen survivin in healthy donors and cancer patients. J. Immunol. 2008, 181:431.
22. Yang J., Huston L., Berger D., Danke N.A., Liu A.W., Disis M.L., Kwok W.W. Expression of HLA-DP0401 molecules for identification of DP0401 restricted antigen specific T cells. J. Clin. Immunol. 2005, 25:428.
23. Zarour H.M., Maillere B., Brusic V., Coval K., Williams E., Pouvelle-Moratille S., Castelli F., Land S., Bennouna J., Logan T., Kirkwood J.M. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells. Cancer Res. 2002, 62:213.
24. Zeng G., Wang X., Robbins P.F., Rosenberg S.A., Wang R.F. CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proc. Natl. Acad. Sci. USA 2001, 98:3964.